In this study, we report the development of BM-homing allogeneic CAR33-NKT cells for targeting BM-resident myeloid malignancies such as AML and MDS, leveraging human HSPC gene engineering and a clinically guided culture method. This evidence concerns the gene PSMA7 and myelodysplastic syndrome.